Friendship Biological-B (02496.HK): Y225 (aemisazumab injection) obtains IND approval from NMPA

The Zhitong Finance and Economics APP news, FriendMed Bio-B (02496.HK) announced that on December 23, 2025, its clinical trial (IND) application for the biological similar drug Y225 has been approved by the National Medical Products Administration (NMPA) of the People's Republic of China.